Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis

References

• Oudard S, Beuselinck B, Decoene J, et al. Sunitinib for the treatment of metastatic renal cell carcinoma. Cancer Treat Rev 2011;37(3):178-84
   PubMedGoogle Scholar
• Theou-Anton N, Faivre S, Dreyer C, et al. Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer. Drug Saf 2009;32(9):717-34
   PubMedGoogle Scholar
• Sunitinib drug monograph. Cancer Care Ontario drug formulary. Available from: www.cancercare.on.ca/toolbox/drugs/drugformulary
   Google Scholar
• Demetri GD, Garrett CR, Schöffski P, et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res 2012;18(11):3170-9
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O. Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. J Egypt NatlCanc Inst 2013;25(4):165-71
   PubMedGoogle Scholar
• Abdel-Rahman O, Fouad M. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2014. [Epub ahead of print]
   Google Scholar
• Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and Meta analysis. Expert Rev Anticancer Ther 2014;1-8. [Epub ahead of print]
   Google Scholar
• Fabbrocini G, Cameli N, Romano MC, et al. Chemotherapy and skin reactions. J Exp Clin Cancer Res 2012;31:50
   PubMedGoogle Scholar
• Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib; an updated systematic review and meta analysis. Expert Rev Anticancer Ther 2014;14(6):751-60
   PubMed Web of Science ®Google Scholar
• Billemont B, Barete S, Meric JB, et al. Skin toxicity of sunitinib: Prospective analysis in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol In ASCO Annual Meeting Proceedings 2008;26(15 Suppl):16146
   Google Scholar
• Pfizer pharma, sutent prescribing information. Available from: www.pfizer.ca/fr/our_products/products/monograph/147
   Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviewsand Meta-Analyses: The PRISMA Statement. J Clin Epidemiol 2009;62(10):1006-12
   PubMed Web of Science ®Google Scholar
• National cancer institute, common toxicity criteria. Available from: http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf [Last accessed on 18 Dec 2013]
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-88
   PubMedGoogle Scholar
• Yoshiji H, Kuriyama S, Yoshii J, et al. halting the interaction between vascular endothelial growthfactor and its receptors attenuates liver carcinogenesis in mice. Hepatology 2004;39:1517-24
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369(8):722-31
   PubMed Web of Science ®Google Scholar
• Huynh H, Ngo VC, Choo SP, et al. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. Curr Cancer DrugTargets 2009;9(6):738-47
   PubMedGoogle Scholar
• Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with Sunitinib, axitinib, cediranib or regorafenib; an updated systematic review and comparative meta analysis. Crit Rev Oncol Hematol 2014; Epub ahead of print
   Google Scholar
• Abdel-Rahman O, Fouad M. Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis. Expert Rev Anticancer Ther 2014;14(9):1063-73
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Fouad M. Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. Crit Rev Oncol Hematol. 2014; Epub ahead of print
   Google Scholar
• Huggins RH, Kuzel TM, Anderson RT, et al. Hand foot skin reaction (HFSR) by the multikinase inhibitors (MKIs) sorafenib and sunitinib: impact on quality of life (QoL). In J Clin Oncol (Meeting Abstracts) 2008;26(15 Suppl):16122
   Google Scholar
• Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009;10(8):757-63
   PubMed Web of Science ®Google Scholar
• Lankheet N, Mallo H, Haanen JB, et al. Quantification of sunitinib in sweat secretion. J Clin Oncol In ASCO Annual Meeting Proceedings 2010;28(15 Suppl):e15094
   Google Scholar
• Erdem L, Giovannetti E, Leon LG. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. Curr Top Med Chem 2012;12(15):1649-59
   PubMed Web of Science ®Google Scholar
• Chen D, Gordon J, Ibrahim O, et al. Management of dermatologic toxicities associated with epidermal growth factor inhibitors (EGFRIs) and multikinase inhibitors (MKIs). J Clin Oncol (Meeting Abstracts) 2011;29(15 Suppl):e19624
   Google Scholar
• Poprach I, Pavlik T, Melichar B, et al. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. Ann Oncol 2012;23(12):3137-43
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-90
   PubMed Web of Science ®Google Scholar
• Chu D, Lacouture ME, Weiner E, et al. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a metaanalysis. Clin Genitourin Cancer 2009;7(1):11-19
   PubMedGoogle Scholar
• Négrier S, Gravis G, Pérol D, et al. Temsirolimus and bevacizumab, or sunitinib, or interferonalfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 2011;12(7):673-80
   PubMed Web of Science ®Google Scholar
• Socinski MA, Scappaticci FA, Samant M, et al. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol 2010;5(3):354-60
   PubMed Web of Science ®Google Scholar
• Wildiers H, Fontaine C, Vuylsteke P, et al. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010;123(2):463-9
   PubMed Web of Science ®Google Scholar
• Crown JP, Diéras V, Staroslawska E, et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol 2013;31(23):2870-8
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial. J Clin Oncol 2012;30(17):2070-8
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Lin DY, et al. Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: results of a Randomized Phase III Trial. J Clin Oncol 2013;31(32):406775
   Google Scholar
• Bergh J, Bondarenko IM, Lichinitser MR, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 2012;30(9):921-9
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364(6):501-13
   PubMed Web of Science ®Google Scholar
• Groen HJ, Socinski MA, Grossi F, et al. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). Ann Oncol 2013;24(9):2382-9
   PubMed Web of Science ®Google Scholar
• Barrios CH, Liu MC, Lee SC, et al. Phase III randomized trial of sunitinib versus capecitabine inpatients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010;121(1):121-31
   PubMed Web of Science ®Google Scholar
• Michaelson MD, Oudard S, Ou YC, et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 2014;32(2):76-82
   PubMed Web of Science ®Google Scholar